EU/3/14/1429: Orphan designation for the treatment of ovarian cancer

N-methyl-4-({4-[({3-methyl(methylsulfonyl)aminopyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride (defactinib)


On 15 January 2015, orphan designation (EU/3/14/1429) was granted by the European Commission to TMC Pharma Services Ltd, United Kingdom, for N-methyl-4-({4-[({3-methyl(methylsulfonyl)aminopyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride for the treatment of ovarian cancer.

Key facts

Active substance
N-methyl-4-({4-[({3-methyl(methylsulfonyl)aminopyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride (defactinib)
Intended use
Treatment of ovarian cancer
Orphan designation status
EU designation number
Date of designation

TMC Pharma (EU) Limited
7A Durands Court
45 Parnell Street
Co. Waterford
X91 P381
Tel. + 353766705745

Review of designation

This medicine is now known as defactinib.

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

May 2022The sponsor’s address was updated in May 2022.
March 2021The sponsor’s address was updated in March 2021.
July 2019The sponsorship was transferred to TMC Pharma (EU) Limited, Ireland, in July 2019.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating